|
1
|
Pei L and Melmed S: Isolation and
characterization of a pituitary tumor-transforming gene (PTTG). Mol
Endocrinol. 11:433–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Puri R, Tousson A, Chen L and Kakar SS:
Molecular cloning of pituitary tumor transforming gene 1 from
ovarian tumors and its expression in tumors. Cancer Lett.
163:131–139. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kakar SS: Molecular cloning, genomic
organization and identification of the promoter for the human
pituitary tumor transforming gene (PTTG). Gene. 240:317–324. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang X, Horwitz GA, Prezant TR, Valentini
A, Nakashima M, Bronstein MD and Melmed S: Structure, expression
and function of human pituitary tumor-transforming gene (PTTG). Mol
Endocrinol. 13:156–166. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boelaert K, McCabe CJ, Tannahill LA,
Gittoes NJ, Holder RL, Watkinson JC, Bradwell AR, Sheppard MC and
Franklyn JA: Pituitary tumor transforming gene and fibroblast
growth factor-2 expression: potential prognostic indicators in
differentiated thyroid cancer. J Clin Endocrinol Metab.
88:2341–2347. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Genkai N, Homma J, Sano M, Tanaka R and
Yamanaka R: Increased expression of pituitary tumor-transforming
gene (PTTG)-1 is correlated with poor prognosis in glioma patients.
Oncol Rep. 15:1569–1574. 2006.PubMed/NCBI
|
|
7
|
Karra H, Repo H, Ahonen I, Löyttyniemi E,
Pitkӓnen R, Lintunen M, Kuopio T, Söderström M and Kronqvist P:
Cdc20 and securin overexpression predict short-term breast cancer
survival. Br J Cancer. 110:2905–2913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Demeure MJ, Coan KE, Grant CS, Komorowski
RA, Stephan E, Sinari S, Mount D and Bussey KJ: PTTG1
overexpression in adrenocortical cancer is associated with poor
survival and represents a potential therapeutic target. Surgery.
154:1405–1416. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abbud RA, Takumi I, Barker EM, Ren SG,
Chen DY, Wawrowsky K and Melmed S: Early multipotential pituitary
focal hyperplasia in the alpha-subunit of glycoprotein
hormone-driven pituitary tumor-transforming gene transgenic mice.
Mol Endocrinol. 19:1383–1391. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hitomi T, Habu T, Kobayashi H, et al:
Downregulation of Securin by the variant RNF213 R4810K
(rs112735431, G>A) reduces angiogenic activity of induced
pluripotent stem cell-derived vascular endothelial cells from
moyamoya patients. Biochem Biophys Res Commun. 438:13–19. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chesnokova V, Kovacs K, Castro AV, Zonis S
and Melmed S: Pituitary hypoplasia in Pttg-/- mice is protective
for Rb+/- pituitary tumorigenesis. Mol Endocrinol. 19:2371–2379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tfelt-Hansen J, Yano S, Bandyopadhyay S,
Carroll R, Brown EM and Chattopadhyay N: Expression of pituitary
tumor transforming gene (PTTG) and its binding protein in human
astrocytes and astrocytoma cells: function and regulation of PTTG
in U87 astrocytoma cells. Endocrinology. 145:4222–4231. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang L, Wang J, Wang Y, Fu Q, Lei YH, Nie
ZY, Qiu J and Bao TY: Protective effect of exogenous matrix
metalloproteinase-9 on chronic renal failure. Exp Ther Med.
7:329–334. 2014.PubMed/NCBI
|
|
14
|
Toth M, Chvyrkova I, Bernardo MM,
Hernandez-Barrantes S and Fridman R: Pro-MMP-9 activation by the
MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and plasma membranes.
Biochem Biophys Res Commun. 308:386–395. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gouda HM, Khorshied MM, El Sissy MH,
Shaheen IA and Mohsen MM: Association between matrix
metalloproteinase 2 (MMP2) promoter polymorphisms and the
susceptibility to non-Hodgkin's lymphoma in Egyptians. Ann Hematol.
93:1313–1318. 2014.PubMed/NCBI
|
|
16
|
Iizuka S, Ishimaru N and Kudo Y: Matrix
metalloproteinases: the gene expression signatures of head and neck
cancer progression. Cancers (Basel). 6:396–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lai X, Liao J, Lin W, et al: Inhibitor of
DNA-binding protein 1 knockdown arrests the growth of colorectal
cancer cells and suppresses hepatic metastasis in vivo. Oncol Rep.
32:79–88. 2014.PubMed/NCBI
|
|
19
|
Xia H, Ma YF, Yu CH, Li YJ, Tang J, Li JB,
Zhao YN and Liu Y: Aquaporin 3 knockdown suppresses tumor growth
and angiogenesis in experimental non-small cell lung cancer. Exp
Physiol. 99:974–984. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen JS, Li HS, Huang JQ, Zhang LJ, Chen
XL, Wang Q, Lei J, Feng JT, Liu Q and Huang XH: Down-regulation of
Gli-1 inhibits hepatocellular carcinoma cell migration and
invasion. Mol Cell Biochem. 393:283–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu J, Shen L, Yang L, Hu S, Xu L and Wu
S: High expression of β3GnT8 is associated with the metastatic
potential of human glioma. Int J Mol Med. 33:1459–1468.
2014.PubMed/NCBI
|
|
22
|
Wen X, Huang A, Liu Z, Liu Y, Hu J, Liu J
and Shuai X: Downregulation of ROCK2 through nanocomplex sensitizes
the cytotoxic effect of temozolomide in U251 glioma cells. PLoS
One. 9:e920502014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liang HS, Zhong YH, Luo ZJ, Huang Y, Lin
HD, Luo M, S-Zhan, Su HX, Zhou SB and Xie KQ: Comparative analysis
of protein expression in differentiated thyroid tumours: a
multicentre study. J Int Med Res. 37:927–938. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang H, Zhong Y, Luo Z, Huang Y, Lin H,
Luo M, Zhan S, Xie K, Ma Y and Li QQ: Assessment of biomarkers for
clinical diagnosis of papillary thyroid carcinoma with distant
metastasis. Int J Biol Markers. 25:38–45. 2010.PubMed/NCBI
|
|
25
|
Malik MT and Kakar SS: Regulation of
angiogenesis and invasion by human pituitary tumor transforming
gene (PTTG) through increased expression and secretion of matrix
metalloproteinase-2 (MMP-2). Mol Cancer. 5:612006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xia YH, Li M, Fu DD, Xu SL, Li ZG, Liu D
and Tian ZW: Effects of PTTG down-regulation on proliferation and
metastasis of the SCL-1 cutaneous squamous cell carcinoma cell
line. Asian Pac J Cancer Prev. 14:6245–6248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wieczorek E, Jablonska E, Wasowicz W and
Reszka E: Matrix metalloproteinases and genetic mouse models in
cancer research: a mini-review. Tumour Biol. 36:163–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li H, Yin C, Zhang B, et al: PTTG1
promotes migration and invasion of human non-small cell lung cancer
cells and is modulated by miR-186. Carcinogenesis. 34:2145–2155.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li XX, Huang LY, Peng JJ, Liang L, Shi DB,
Zheng HT and Cai SJ: Klotho suppresses growth and invasion of colon
cancer cells through inhibition of IGF1R-mediated PI3K/AKT pathway.
Int J Oncol. 45:611–618. 2014.PubMed/NCBI
|
|
30
|
Salehi F, Scheithauer BW, Sharma S, Kovacs
K, Lloyd RV, Cusimano MD and Munoz DG: Immunohistochemical
expression of PTTG in brain tumors. Anticancer Res. 33:119–122.
2013.PubMed/NCBI
|
|
31
|
Zhang J, Yang Y, Chen L, Zheng D and Ma J:
Overexpression of pituitary tumor transforming gene (PTTG) is
associated with tumor progression and poor prognosis in patients
with esophageal squamous cell carcinoma. Acta Histochem.
116:435–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zatelli MC, Tagliati F, Amodio V, Buratto
M, Pelizzo M, Pansini G, Bondanelli M, Ambrosio MR and Degli Uberti
EC: Role of pituitary tumour transforming gene 1 in medullary
thyroid carcinoma. Anal Cell Pathol (Amst). 33:207–216. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim JW, Song JY, Lee JM, Lee JK, Lee NW,
Yeom BW and Lee KW: Expression of pituitary tumor-transforming gene
in endometrial cancer as a prognostic marker. Int J Gynecol Cancer.
18:1352–1359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jia W, Lu R, Jia G, Ni M and Xu Z:
Expression of pituitary tumor transforming gene (PTTG) in human
pituitary macroadenomas. Tumour Biol. 34:1559–1567. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang
Q, Wang Y, Lu N, He S, Zhan Q, Liu S and Xu N: PTTG overexpression
promotes lymph node metastasis in human esophageal squamous cell
carcinoma. Cancer Res. 69:3283–3290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pan SJ, Zhan SK, Pei BG, Sun QF, Bian LG
and Sun BM: MicroRNA-149 inhibits proliferation and invasion of
glioma cells via blockade of AKT1 signaling. Int J Immunopathol
Pharmacol. 25:871–881. 2012.PubMed/NCBI
|
|
37
|
Nakabayashi H and Shimizu K: Involvement
of Akt/NF-κB pathway in antitumor effects of parthenolide on
glioblastoma cells in vitro and in vivo. BMC Cancer. 12:4532012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dudley A, Sater M, Le PU, Trinh G, Sadr
MS, Bergeron J, Deleavey GF, Bedell B, Damha MJ and Petrecca K: DRR
regulates AKT activation to drive brain cancer invasion. Oncogene.
33:4952–4960. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Thompson AD III and Kakar SS: Insulin and
IGF-1 regulate the expression of the pituitary tumor transforming
gene (PTTG) in breast tumor cells. FEBS Lett. 579:3195–3200. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pan H, Gao F, Papageorgis P, Abdolmaleky
HM, Faller DV and Thiagalingam S: Aberrant activation of
gamma-catenin promotes genomic instability and oncogenic effects
during tumor progression. Cancer Biol Ther. 6:1638–1643. 2007.
View Article : Google Scholar : PubMed/NCBI
|
